EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Redhill Biopharma Ltd (RDHL) fair value: what the stock is really worth

We calculate from audited financials what Redhill Biopharma Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US7574681034

RB Redhill Biopharma Ltd logo Thin data Jul 24, 2026

Redhill Biopharma Ltd

RDHL · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.4675 · Overvalued (−14%)
!Quality 27/100
!Weak Growth (revenue 5y −66.2 %/yr)
!Loss-making · -150.0% net margin (TTM)
!High debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 15 out of 100
Watch Redhill Biopharma Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10,360 $0.5410 Fair Value $0.4675 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

60‑month range $0.5410 – $10,360 · fair‑value band $0.3485 – $0.6970 · the $0.5431 price screens above the $0.4675 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.

Follow Redhill Biopharma in your weekly email

Every Wednesday you see whether Redhill Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Show more

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Stock analysis

Redhill Biopharma Ltd (RDHL) currently trades at $0.5431, while our model-based Fair Value estimate is $0.4675, implying the stock looks roughly 16.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.3485 (bear) to $0.6970 (bull), the price of $0.5431 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Redhill Biopharma Ltd reported revenue of $286K in FY2025 versus $85.8M in FY2021, a compound −76.0%/yr. Reported net income was −$429K in FY2025.

Key figures

Market cap $4.2M · P/S ratio 14.8 · Net margin −150% · Return on equity −1,709% · Return on assets (EBIT) −25.8% · Operating margin −2,765% · Revenue (TTM) $286K · Revenue growth (YoY) +58.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 78% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −14%, RDHL screens richer than that median.

Fair Value models

Bear $0.3485 Fair Value $0.4675 Bull $0.6970
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.4100 $0.5500 $0.8200 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.4100 $0.5500 $0.8200 54

Open the full fair value analysis →

Notify me when RDHL reaches fair value

Put RDHL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 27/100

Of which business quality 27 · Market factors (momentum, volatility) 0

Profitability 3
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 16
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−96.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−83.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−66.2%
Start year 2020 (pandemic)
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−99.0% (2020) → −2,765.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

RDHL screens 16% overvalued. Compare with Merck KGaA →

Compare Redhill Biopharma Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −14% · Above median
Profitability
Return on assets −23% · Bottom 25%
Net margin (TTM) −150% · Bottom 25%
Growth and dividend
Revenue growth 59% · Top 25%
Balance sheet
Debt / equity 19.59× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.99× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 14.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 14
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Redhill Biopharma Ltd · Fair Value
$0.4675 −16%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Redhill Biopharma Ltd Fair Value". https://www.fairvalue-calculator.com/stock/RDHL

Frequently asked questions

Is Redhill Biopharma Ltd (RDHL) overvalued or undervalued?
As of Jul 24, 2026, our model estimates a fair value of $0.4675 versus a price of $0.5431, about −14% upside (overvalued).
What is the fair value of RDHL?
Our model-based fair value for Redhill Biopharma Ltd is $0.4675 (as of Jul 24, 2026), built from audited fundamentals. The current price: $0.5431.
What is the quality score of RDHL?
Redhill Biopharma Ltd has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Redhill Biopharma Ltd (RDHL)?
Our model-based price target is the fair value of $0.4675 (as of Jul 24, 2026) from 1 valuation models. Cautious scenario $0.3485, optimistic scenario $0.6970. It is a calculation from audited fundamentals, not an analyst target.
What is the Redhill Biopharma Ltd stock forecast for 2026?
Our models put fair value at $0.4675, about −14% upside versus a price of $0.5431 (overvalued). Cautious scenario $0.3485, optimistic scenario $0.6970. The calculation is refreshed regularly with new filings.
What is the revenue of Redhill Biopharma Ltd (RDHL)?
Redhill Biopharma Ltd reported trailing-twelve-month revenue of about $286K (latest available figure, as of Jul 24, 2026).
What is the intrinsic value of Redhill Biopharma Ltd (RDHL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Redhill Biopharma Ltd it is $0.4675 per share (as of Jul 24, 2026), against a price of $0.5431. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Redhill Biopharma Ltd stock overvalued or undervalued in 2026?
As of Jul 24, 2026, RDHL trades above its calculated fair value: price $0.5431, fair value $0.4675, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RDHL?
No. The price is what the market pays today ($0.5431); the fair value is what the company's own numbers justify ($0.4675). For Redhill Biopharma Ltd the two are $0.0756 per share apart. That gap is exactly why we show both numbers side by side.
How much is Redhill Biopharma Ltd worth?
The market values Redhill Biopharma Ltd at about $4.2M (market capitalisation, as of Jul 24, 2026). Per share that is $0.5431; our models calculate a fair value of $0.4675 per share.
What do the bullish and bearish scenarios say about RDHL?
Our models span a range for Redhill Biopharma Ltd: cautious scenario $0.3485, base $0.4675, optimistic $0.6970 per share (as of Jul 24, 2026, price $0.5431). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Redhill Biopharma Ltd (RDHL)?
Balance-sheet figures for Redhill Biopharma Ltd (as of Jul 24, 2026): debt of 19.59 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is RDHL from its 52-week high?
Redhill Biopharma Ltd trades at $0.5431, about 78% below its 52-week high of $2.52 and at the low of $0.5410 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4675 is for.
Which stocks are comparable to Redhill Biopharma Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Redhill Biopharma Ltd stock attractive at the current price?
The data as of Jul 24, 2026: price $0.5431, calculated fair value $0.4675 (−14%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RDHL calculated?
We run Redhill Biopharma Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4675, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Redhill Biopharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Redhill Biopharma Ltd (RDHL)?
The closing price on Sep 23, 2026 was $0.5431. Our model-based fair value is $0.4675, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Redhill Biopharma Ltd right now?
A fairly wide model range ($0.3485 to $0.6970) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Redhill Biopharma Ltd

How large is the market capitalisation of Redhill Biopharma Ltd (RDHL)?
The market capitalisation of Redhill Biopharma Ltd is $4.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Redhill Biopharma Ltd (RDHL)?
The price-to-sales ratio of Redhill Biopharma Ltd is 14.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Redhill Biopharma Ltd (RDHL)?
The net margin of Redhill Biopharma Ltd is −150% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Redhill Biopharma Ltd (RDHL)?
The return on equity (ROE) of Redhill Biopharma Ltd is −1,709% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Redhill Biopharma Ltd (RDHL)?
On an EBIT basis the return on assets of Redhill Biopharma Ltd is −25.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Redhill Biopharma Ltd (RDHL)?
The operating margin of Redhill Biopharma Ltd is −2,765% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Redhill Biopharma Ltd (RDHL)?
Revenue at Redhill Biopharma Ltd is growing +58.6% versus a year earlier (3y avg −83.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Redhill Biopharma Ltd (RDHL) generate?
The free cash flow of Redhill Biopharma Ltd is −$9.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Redhill Biopharma Ltd (RDHL) hold?
Redhill Biopharma Ltd holds more cash than debt, $2.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Redhill Biopharma Ltd in the live analysis

One click puts Redhill Biopharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.